These data raised hypotheses regarding possible augmentation of EGFR blockade with cyclin-dependent kinase 4/6 (CDK4/6) inhibition, analogous to data in breast cancer where such agents act synergistically with PI3K blockade30. This evidence concerns the gene CDK4 and breast carcinoma.